» Articles » PMID: 8758243

Karnofsky and ECOG Performance Status Scoring in Lung Cancer: a Prospective, Longitudinal Study of 536 Patients from a Single Institution

Overview
Journal Eur J Cancer
Specialty Oncology
Date 1996 Jun 1
PMID 8758243
Citations 207
Authors
Affiliations
Soon will be listed here.
Abstract

The Karnofsky's index of performance status (KPS) and the Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) are widely used methods of assessing the functional status of cancer patients. In this study, we compare their predictive validity, and suggest a table of transformation between scales. 536 consecutive lung cancer patients were assigned both KPS and ECOG PS scores before, during and after treatment (in all, 1656 assignments). Patients were accurately staged at diagnosis, and carefully re-evaluated at each follow-up visit. Multiple clinical, laboratory and instrumental data were recorded along with performance status assessments. Survival times were measured from the pathological diagnosis. KPS and ECOG PS assignments were strongly related to each other (Spearman R = -0.869). Correlation between scales persisted unchanged in pretreatment and post-treatment assessments, advanced and limited diseases, response or non-response to treatment, and different assessors (R indices ranging from -0.825 to -0.901). A three-point conversion table showed the highest rate of success with an overall percentage of agreement exceeding 84% (grade 1: KPS = 100, 90, 80 and ECOG PS = 0, 1; grade 2: KPS = 70, 60 and ECOG PS = 2; grade 3: KPS < 60 and ECOG PS = 3, 4). Both univariate and multivariate analyses of survival documented the predictive validity of the two scales. However, KPS showed less ability than ECOG PS to discriminate patients with different prognosis. Because of the better predictive ability shown in this study, ECOG PS should be preferred to KPS. A general consensus on the scale to use could avoid problems of conversion, which is not always easy and free of errors.

Citing Articles

The association of metabolic positron emission tomography/computed tomography parameters with survival in small cell lung cancer.

Turk M, Komurcuoglu B, Aguloglu N, Ciftci T, Fidan M, Colak S Ann Saudi Med. 2025; 45(1):25-32.

PMID: 39929786 PMC: 11810877. DOI: 10.5144/0256-4947.2025.25.


Survival and quality of life after first-time diagnosis of brain metastases: a multicenter, prospective, observational study.

Yri O, Astrup G, Karlsson A, van Helvoirt R, Hjermstad M, Husby K Lancet Reg Health Eur. 2025; 49():101181.

PMID: 39807153 PMC: 11728971. DOI: 10.1016/j.lanepe.2024.101181.


Analysis of Inertial Measurement Unit Data for an AI-Based Physical Function Assessment System Using In-Clinic-like Movements.

Kouno N, Takahashi S, Takasawa K, Komatsu M, Ishiguro N, Takeda K Bioengineering (Basel). 2025; 11(12.

PMID: 39768050 PMC: 11673146. DOI: 10.3390/bioengineering11121232.


Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy.

Wang L, Diao Y, Ma X, Luo Y, Guo Q, Chen X World J Gastrointest Surg. 2024; 16(10):3277-3287.

PMID: 39575283 PMC: 11577402. DOI: 10.4240/wjgs.v16.i10.3277.


Effect of Telenursing on Supportive Care Needs in Patients with Melanoma and Lung Cancer on Targeted Therapies: A Randomised Controlled Trial Study Protocol.

De Leo A, Liquori G, Spano A, Panattoni N, Dionisi S, Iacorossi L Methods Protoc. 2024; 7(5).

PMID: 39452792 PMC: 11510742. DOI: 10.3390/mps7050078.